The Met receptor tyrosine kinase is the prototypic member of a small subfamily of growth factor receptors that when activated induce mitogenic, motogenic, and morphogenic cellular responses.

Receptor tyrosine kinases (RTKs ... for RTKs in part due to an emphasis on the discovery of ATP-competitive tyrosine kinase domain inhibitors. Biased ligands hold therapeutic promise due to ...

which in turn trigger cytosolic tyrosine kinase activity, are referred to as receptor tyrosine kinases (RTKs). Some examples include the epidermal growth factor receptor, platelet-derived growth ...

EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs), given their low molecular weight, may be able to reach a higher concentration in brain tissues. Various reports and small studies ...

Our data suggest that EGFR tyrosine kinase mutations can be used to identify the subgroup of patients with non–small-cell lung cancer in whom this growth factor receptor may be essential to ...

One of the proteins, called epidermal growth factor receptor (EGFR), belonged to ... the new generation of anti-cancer drugs called Tyrosine Kinase Inhibitors (TKIs). Yet these are some of the ...

Upon binding with an external ligand, the cytoplasm domain of the receptor tyrosine kinase undergoes autophosphorylation and becomes active, initiating a cascade of signaling pathways that result ...

Tyrosine kinase inhibitors are particularly important agents because these high-affinity cell surface receptors play a critical role in the progression of many cancers. Tyrosine kinases are ...

Lenvatinib was associated with the most significant probability of producing all grades of cardiovascular injury and hypertension. Vascular endothelial growth factor receptor tyrosine kinase ...